Jiayi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiayi Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dawei Chen
Shandong First Medical University and Shandong Academy of Medical Sciences
2 shared publications - Baoqing Tian
Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
1 shared publication - Jiao Ren
First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication - Jiaxin Wang
Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
1 shared publication - Jingxin Zhang
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440, Jiyan Road, Jinan, Shandong 250117, China
1 shared publication Jupeng Yuan
Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (42) , 4564-4580
ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression
Radiotherapy resistance represents a critical barrier to successful treatment of esophageal squamous cell carcinoma (ESCC), driving tumor recurrence and poor patient survival. We identify constitutive overexpression of integrin α5 (ITGA5) as a key molecular determinant of ESCC radioresistance. Clinically, elevated ITGA5 expression correlates with radiation therapy failure and reduced overall survival. Mechanistically, ITGA5 sustains persistent FAK/AKT/GSK-3β/β-Catenin signaling activation, which drives MYC-dependent transactivation of RAD51AP1. This signaling axis enhances homologous recombination repair efficiency by facilitating RAD51 chromatin loading, enabling effective DNA damage resolution and radioresistance maintenance. Genetic validation confirms the indispensable roles of RAD51AP1 and MYC in this process. Critically, pharmacological inhibition of ITGA5 with ATN-161 restores radiation sensitivity in preclinical models, suppressing tumor growth and enhancing DNA damage accumulation. Our work defines the ITGA5/FAK/β-catenin/MYC/RAD51AP1 pathway as a key mechanistic driver of radioresistance and validates ITGA5 as a potential clinical target for ESCC therapy.
- 4 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (42) , 4564-4580
Open AccessITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression
Radiotherapy resistance represents a critical barrier to successful treatment of esophageal squamous cell carcinoma (ESCC), driving tumor recurrence and poor patient survival. We identify constitutive overexpression of integrin α5 (ITGA5) as a key molecular determinant of ESCC radioresistance. Clinically, elevated ITGA5 expression correlates with radiation therapy failure and reduced overall survival. Mechanistically, ITGA5 sustains persistent FAK/AKT/GSK-3β/β-Catenin signaling activation, which drives MYC-dependent transactivation of RAD51AP1. This signaling axis enhances homologous recombination repair efficiency by facilitating RAD51 chromatin loading, enabling effective DNA damage resolution and radioresistance maintenance. Genetic validation confirms the indispensable roles of RAD51AP1 and MYC in this process. Critically, pharmacological inhibition of ITGA5 with ATN-161 restores radiation sensitivity in preclinical models, suppressing tumor growth and enhancing DNA damage accumulation. Our work defines the ITGA5/FAK/β-catenin/MYC/RAD51AP1 pathway as a key mechanistic driver of radioresistance and validates ITGA5 as a potential clinical target for ESCC therapy.
- Open Access
- 22 May 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study
Background: Although gemcitabine plus nab-paclitaxel (Gem-NabP), modified FOLFIRINOX (mFOLFIRINOX), and NALIRIFOX are all recommended by current clinical guidelines as first-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC), the optimal regimen in real-world practice remains uncertain. Objective: To compare the efficacy and safety of different first-line chemotherapy regimens for mPDAC. Design: This was a single-center retrospective study. We included 215 patients with previously untreated mPDAC who received first-line chemotherapy at our institution between September 2023 and February 2025: Gem-NabP (n = 121), mFOLFIRINOX ( n = 55), and NALIRIFOX ( n = 39). Methods: The primary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), while overall survival (OS) was a secondary endpoint. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models. Exploratory subgroup analyses were also performed. Results: NALIRIFOX showed the most favorable efficacy profile, with a median PFS of 9.0 months, a 6-month OS rate of 92.0%, an ORR of 30.77%, and a DCR of 89.74%, compared with 3.5 months, 74.6%, 18.18%, and 64.46% in the Gem-NabP group and 5.0 months, 82.6%, 16.36%, and 76.36% in the mFOLFIRINOX group, respectively (PFS, p < 0.001; ORR, p = 0.171; DCR, p = 0.007). Median OS was not reached in any group, and the between-group difference in OS was not statistically significant ( p = 0.062). In multivariable Cox analyses, both mFOLFIRINOX and NALIRIFOX remained associated with lower risks of disease progression and death than Gem-NabP, whereas alcohol consumption was independently associated with poorer survival. Toxicities were manageable across regimens, with most adverse events being Grade 1-2 and no treatment-related deaths. Grade ⩾3 adverse events were infrequent and generally comparable among groups. Exploratory analyses suggested a more favorable response distribution with NALIRIFOX in patients with mild-to-moderate cancer pain and those with tumors in the pancreatic head, neck, or tail. Conclusion: In this retrospective single-center cohort, NALIRIFOX was associated with longer PFS and favorable short-term survival, with manageable toxicity. These findings require validation in larger prospective multicenter studies.
- 22 May 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessComparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study
Background: Although gemcitabine plus nab-paclitaxel (Gem-NabP), modified FOLFIRINOX (mFOLFIRINOX), and NALIRIFOX are all recommended by current clinical guidelines as first-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC), the optimal regimen in real-world practice remains uncertain. Objective: To compare the efficacy and safety of different first-line chemotherapy regimens for mPDAC. Design: This was a single-center retrospective study. We included 215 patients with previously untreated mPDAC who received first-line chemotherapy at our institution between September 2023 and February 2025: Gem-NabP (n = 121), mFOLFIRINOX ( n = 55), and NALIRIFOX ( n = 39). Methods: The primary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), while overall survival (OS) was a secondary endpoint. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models. Exploratory subgroup analyses were also performed. Results: NALIRIFOX showed the most favorable efficacy profile, with a median PFS of 9.0 months, a 6-month OS rate of 92.0%, an ORR of 30.77%, and a DCR of 89.74%, compared with 3.5 months, 74.6%, 18.18%, and 64.46% in the Gem-NabP group and 5.0 months, 82.6%, 16.36%, and 76.36% in the mFOLFIRINOX group, respectively (PFS, p < 0.001; ORR, p = 0.171; DCR, p = 0.007). Median OS was not reached in any group, and the between-group difference in OS was not statistically significant ( p = 0.062). In multivariable Cox analyses, both mFOLFIRINOX and NALIRIFOX remained associated with lower risks of disease progression and death than Gem-NabP, whereas alcohol consumption was independently associated with poorer survival. Toxicities were manageable across regimens, with most adverse events being Grade 1-2 and no treatment-related deaths. Grade ⩾3 adverse events were infrequent and generally comparable among groups. Exploratory analyses suggested a more favorable response distribution with NALIRIFOX in patients with mild-to-moderate cancer pain and those with tumors in the pancreatic head, neck, or tail. Conclusion: In this retrospective single-center cohort, NALIRIFOX was associated with longer PFS and favorable short-term survival, with manageable toxicity. These findings require validation in larger prospective multicenter studies.